๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Viking Therapeutics, Inc. (VKTX)
NASDAQ: VKTX ยท Real-Time Price ยท USD
24.77
-1.07 (-4.14%)
At close: Nov 20, 2026, 4:00 PM EST
25.10
+0.33 (1.33%)
After-hours: Nov 20, 2026, 7:56 PM EST
โ† View all transcripts

Jefferies Global Healthcare Conference

Nov 18, 2026

Summary

The first maintenance study showed placebo-like tolerability and encouraging weight and lipid maintenance on less-frequent VK2735 dosing; a second study is underway, with results expected around mid-2027. Commercial planning targets a 2029 launch, while phase III data are expected from H2 2027.

Roger Song
Analyst, Jefferies

Welcome everyone to 2026 Jefferies Global Healthcare Conference in London. My name is Roger Song, senior analyst, covers biotech. It is my pleasure to have a fireside chat with Viking Therapeutics. We have a CEO, Brian Lian. We have CFO, Greg. Welcome, gentlemen.

Brian Lian
CEO, Viking Therapeutics

Thanks, Roger. Great to be here. Thanks to Jefferies for the invitation. We have got a packed schedule, really a great meeting, so appreciate it.

Roger Song
Analyst, Jefferies

Excellent. All right. I think we can go right into this. A lot of people are very familiar with Viking. I just met you, Brian, at the ObesityWeek. You host a very nice session with analysts and a couple investors. Can you just give us a little bit highlight about the ObesityWeek, and particularly you share with a little bit of more detailed data from the maintenance part one, and some design for the part two. Which I think is very informative for the future, the further label updates, and the real-world use.

Brian Lian
CEO, Viking Therapeutics

Yeah. We had an analyst and investor event on Friday night in Washington at the ObesityWeek conference. We talked a lot about the recent maintenance study that read out in September. What we talked about new, not only did we see really encouraging maintenance effects when you transition people from a weekly dose to an every other week dose, or weekly to monthly, but we saw really good tolerability. What we tended to see was low rates of the standard GI tolerability signals, nausea, vomiting, constipation, diarrhea. Low rates through the titration window, which dropped substantially off after the titration was done, and were very much like placebo in the maintenance window. So, it was weekly dosing for 21 weeks, and then every other week or monthly dosing for the following 12 weeks after 33 weeks.

What we showed at ObesityWeek was really a histogram of those adverse events through the dosing window, the weekly dosing window, then into the maintenance dosing window. We also showed the effect on lipids through the 21-week window, then through the maintenance window, and we saw a pretty consistent effect on ApoB and non-HDL cholesterol and triglycerides. The lipid effects seemed to track weight loss. So, the greater the weight loss, the greater the lipid reductions. Then we also discussed what the next steps are. We recently initiated a second maintenance study, similar design, where you dose weekly for 21 weeks, then you transition people to a daily dose ranging from, I believe, 10 mg up to 55 mg daily for 12 weeks.

We've added six more arms on the subQ side. So, we have three arms looking at every other week dosing at somewhat higher doses than the first maintenance study, and three arms looking at monthly dosing at somewhat higher doses than the first maintenance study. So, study's underway, it's enrolling well, and we should have those results around middle of the year next year.

Roger Song
Analyst, Jefferies

Excellent. Okay. I think that the data, as you reported, at the top line September, it's well received, and people believe this is a very differentiated profile. When I look at the data on Friday, I think everything's still pretty consistent. The only thing I would pick up is the use, after the first week of the maintenance, you see a dip on the weight loss, but back up pretty quickly, and eventually get to 98% maintenance. So, is that related to the PK exposure? Have you done some modeling, or it's just because the small N?

Brian Lian
CEO, Viking Therapeutics

Yeah. A really interesting phenomenon, what we saw was in that first week during the maintenance window where you transition from weekly to monthly or weekly to every other week, there was maybe a slight rebound. Placebo certainly rebounded.

Roger Song
Analyst, Jefferies

Yeah.

Brian Lian
CEO, Viking Therapeutics

Placebo gained back up.

Roger Song
Analyst, Jefferies

Consistent rebound, yeah.

Brian Lian
CEO, Viking Therapeutics

Yeah, about 40% of the initial weight loss was regained by week 12 with the placebo. You saw a little bit of a slight rebound in the every other week and monthly, but then on the week 8- 12, month two to three, almost a return to weight loss and an improvement in the maintenance signal. Consistent, we saw it in both the monthly and the every other week regimen. Why is that? We do not really know. We do not yet have all of the PK data from that study. The only thing we could think about was maybe there is some sort of a, I do not know, biological re-equilibration to this less frequent regimen that allowed the weight maintenance effect to be established. Do not know.

It is a pretty short window, so we will need to go longer, and we will be going longer in the VANQUISH maintenance period, the VANQUISH extension studies, so we will go out to 52 weeks there. But we noticed as well a curious effect, yeah.

Roger Song
Analyst, Jefferies

Yeah. The good thing is it's a very short window, right? It's you back up to that weight loss. The other thing that's interesting, you down, and then you back to the weight loss. If you follow them longer, I don't know, the trend seems to be maybe you can continue the weight loss if the dose a little bit higher.

Brian Lian
CEO, Viking Therapeutics

Yeah. One of the takeaways from the study for us is that different regimens are going to work better for different people. Certainly, some people on a monthly will continue some degree of weight loss. That's our feeling. The same with every other week. That won't work for everybody, but it'll certainly work for some people. So to have data available from the weekly regimens, every other week regimens, monthly regimens, will let people choose what is best for their lifestyle once they've had some initial weight loss. But everybody responds a little bit differently. There are some people we call sort of super responders. They're ultra-responsive even to low doses. Then some people take a little bit higher dose. So in the super responders, maybe the monthly would work much better than the typical person. Others might not work as well.

Roger Song
Analyst, Jefferies

Yeah. Is that also the reason you are adding more subQ dosing regimen into the part two of the maintenance? I noticed you pushed those higher to 35, which is double the phase III dose in the top kind of induction period. So, the question is, if that data is very interesting, and how are you going to incorporate that into the VANQUISH or maybe the separate study?

Brian Lian
CEO, Viking Therapeutics

Yeah. We've added multiple arms because the tolerability was so encouraging in that maintenance window. It just looked like placebo. We thought we had room to push up on the dose. So we had 90% retention in the monthly dose. We now have gone up, yeah, to 35 mg monthly in the VANQUISH extension. So, we'll see. Over a longer term, does that maintain more people at their VANQUISH 78-week weight loss? So, it'll be interesting to see.

Roger Song
Analyst, Jefferies

Is that possible you can incorporate that into the VANQUISH extension? You will start, I think, early next year, but the part two data not going to read out until mid-year next year.

Brian Lian
CEO, Viking Therapeutics

Yeah. We're going to explore some of these doses in the VANQUISH extension as well. Whether or not we can include language in the label, at a minimum, we would have data to present at conferences and publish and share with investigators. Ideally, we would have some language to include in the label.

Roger Song
Analyst, Jefferies

Excellent. Okay. Would you ever try to switch from the current injectable, tirzepatide and semaglutide, and then move into your injectable, maybe oral even? How you think about that?

Brian Lian
CEO, Viking Therapeutics

Yeah. We've talked a lot about that. Nothing near term. I think that's a good study, switch study from an existing agent onto VK2735, but we haven't yet incorporated that into any study.

Roger Song
Analyst, Jefferies

Okay, good. I think based on the development timeline and the data read-out, you potentially can be the third to the market behind the current approved drug. What is the commercial position right now for your VK2735? We heard a lot of the positive comment from your KOL, but also broadly the community and the patient community, how could they use VK2735 using subQ and oral formulation?

Brian Lian
CEO, Viking Therapeutics

Yeah. Well, I think the goal at Viking has been to create the broadest possible array of options for people to stay on therapy. You really achieve these long-term benefits from sustained use of the agents to keep your weight more in a healthy range. If we can keep people in that healthy range for a long time, everybody wins. How do you keep people there? When people take the weekly injection, a lot of them, when they reach their target weight, they do not know what to do. They switch off, or they begin taking every 10 days, or when they hear food noise, or there is not really an established paradigm. Here, hopefully, we can generate data that support transition from weekly to every other week, and that will work for some people. Transition from weekly to monthly, that will work for others.

For some, maybe transition from the weekly injection to the oral with the same active agent, that will be attractive to some. Having that flexibility and optionality, we think will be very important for long-term persistence of use. The long-term persistence should lead to longer term benefits for everybody in quality of life and function, and long-term cardiovascular health.

Roger Song
Analyst, Jefferies

Yeah. I know in real world, patient already using different regimen and stretch out, yeah, for the maintenance. But seems Viking is taking data-driven approach, right? You want to give people some data to play with and to see, okay, if you use this way, and they will give you this type of the benefit.

Brian Lian
CEO, Viking Therapeutics

Yeah. That's why we would hope from the VANQUISH extensions that we can generate data ultimately that could make it into the label. This regimen provides this weight loss effect, this regimen provides that weight loss effect. So you can have documented protocols to follow. At a minimum, if it doesn't make it into the label, we would publish the results, present them at conferences, and educate through medical science liaisons, the practitioner, to enable the most effective use.

Roger Song
Analyst, Jefferies

Got it. Let's say if you can achieve the profile, better than tirzepatide on the efficacy, maybe comparable on the tolerability, and then you have a lot of the dosing flexibility because your half-life is long. If you can achieve that profile, what will be your commercial strategy? Because we see the obesity space is definitely kind of evolving towards a more consumer-driven, maybe half of the consumer, maybe even go further. How you think about Viking as a biotech company can potentially commercialize it, at least partially?

Brian Lian
CEO, Viking Therapeutics

Yeah. Well, I think to start, we're certainly open to inbound interest from other parties. We've always felt a larger party being involved would generate more value from the program. That said, we're also preparing to launch as an independent entity, and we think the opportunities. We've seen this massive rapid evolution of distribution channels in obesity that's unlike what anybody's ever really seen before.

We're speaking with these direct-to-consumer parties right now. We're speaking with parties who are a little bit more focused on the cash markets. We are speaking with payers, and doing a lot of payer research as to what would be suitable to receive coverage. Very active, rigorous exercise at the company now. We'd be planning to enter the market in the 2029 timeframe, so we have a little bit of time to work this out. But really working hard. We're adding staff in commercial. We've got SVP of Commercial Operations. We've got VP of Market Access. We've got a VP of Medical Affairs. We've got health economics and outcomes research, Head of MSL. So, a nice core team that will be expanded as we get closer to commercialization, and we're looking at all of the options, direct to consumer, covered, direct to employer, across the board.

Roger Song
Analyst, Jefferies

Yeah. Obesity treatment used to be considered as a PCP market, which requires a massive kind of a commercial entity to do that. Now you have many, just like you said, many platforms and many capabilities can do this. Do you think this amount of the commercial infrastructure required to launch the drug is significantly lower than before? If that's the case, how Viking will think about to be able to fund this at least partially again?

Brian Lian
CEO, Viking Therapeutics

Yeah. There's such high demand for these agents that they sell themselves, maybe too strong a-

description, but they really do kind of lead to increased interest from people. Weight loss is something-

Roger Song
Analyst, Jefferies

Patients ask for drugs.

Brian Lian
CEO, Viking Therapeutics

Patients ask for it. They're seeking the drug, and they're willing to pay cash. We think that's an opportunity that really we haven't seen before on this level. It's evidenced by when the shortages occurred, the success of the compounding channels. I mean, it took 15%-20% of the market, and you don't think of compounders as having sales forces or extensive infrastructure. That to us suggests that maybe you don't need a massive sales force and a huge DTC spend. You need to have the right partners. You do need to have some sales presence to raise awareness in the clinician community. But you don't need 1,000 reps and massive infrastructure. We find that really encouraging. Given the size of the market, we don't need to capture 40% of the market.

We can capture less than 10% and see massive upside for Viking. Now, going back to my earlier comment, if it were part of a larger organization, there's more to be gained from a larger presence behind it. But certainly, Viking has a great opportunity as a single entity.

Roger Song
Analyst, Jefferies

Yeah. Awesome. All right. You have another form of the VK2735, its oral version, and then you're running, just like we mentioned earlier, the maintenance study for the transition from subQ to oral. What is the expectation from there? Because you have a subQ to subQ, less frequent, but oral is completely different. What's your PK modeling suggest you can reach similar level, and then how the maintenance level you will look like?

Brian Lian
CEO, Viking Therapeutics

Yeah. Right. Just to give an overview of the oral, we have an oral tablet with the same active pharmaceutical ingredient, and that's currently in two phase III studies, SUNRISE- 1 in obesity and SUNRISE- 2 in obese diabetics. We are in the ongoing maintenance study transitioning people from a 17.5 mg weekly dose to a range of daily orals from, I think, 10 mg to 55 mg. How will that shake out? With the orals, you get lower plasma exposures in any given day. But since you're taking it every day and the drug's got a long half-life, there is some accumulation. How does that play out longer term? We don't really know. We've modeled it quite a bit.

But no substitute for the actual experiment. It will be interesting to see what each of those dose levels demonstrates then over the long term as the plasma levels kind of wash out from the subQ and accumulate from the oral.

We don't know.

Roger Song
Analyst, Jefferies

Mm-hmm. Then that will be considered a very good scenario because now your part one, the subQ to subQ maintenance set a very high bar, right? 90%, 98%. We know historically, maybe 75%, 80% you can maintain this cardiovascular benefit. Is this oral going to sit between, or because it's oral, you can potentially have some trade-off on the maintenance?

Brian Lian
CEO, Viking Therapeutics

Yeah. It's a tough one. I think the way we If you step back just to your point-

Roger Song
Analyst, Jefferies

Yeah.

Brian Lian
CEO, Viking Therapeutics

if you can maintain 75% of that initial weight loss, you will capture most of the cardiometabolic benefits. That would be the range that we would hope to see with the transition from subQ to oral.

Roger Song
Analyst, Jefferies

Got it. Yeah. That's a floor level you want to-

Brian Lian
CEO, Viking Therapeutics

Yeah. We would hope so. Maybe the lower doses be different, but we would hope to, in the mid to high doses, be in that 75% and above maintenance.

Roger Song
Analyst, Jefferies

Got it. Got it. Given the capacity manufacturing peptide is significantly higher than before, also because of the demand. How do you think about the COGS on the oral peptide is evolving? I believe you have a partnership with CordenPharma.

Brian Lian
CEO, Viking Therapeutics

Yeah.

Roger Song
Analyst, Jefferies

You have a contract there. With this changing pricing, did that also change the contracting term, and then how much is the more amount can generate even if the dollar value does not change?

Brian Lian
CEO, Viking Therapeutics

Yeah. We chose doses in the maintenance study and in the phase III studies where the top dose was still reasonably profitable to the company. We've got, as you said, a really great partnership with CordenPharma for multi-ton quantities of API, as well as fill and finish for vials and syringes and auto-injectors and tablets. Pretty full suite of offerings there. We have since the initial agreement was signed, we've added three additional API suppliers at the multi-ton level, that can feed into the Corden line. I think on the initial drug substance, we have a good supply chain in place. We will be building in redundancies on vial and syringe and auto-injector and tablets, but right now, we feel pretty good about the current supply chain.

Where does pricing go? What we've seen, over the past 24- 36 months, we've seen pricing kind of come down a little bit. Nobody's produced these until the last three or four years on the scale that we're seeing today, these peptides. As efficiencies improve and optimization of purification, solvent recycling, all those sorts of things, we would anticipate there to be a further drift down. It's not infinite, but we will likely see some price improvement in the raw materials as time goes on.

Roger Song
Analyst, Jefferies

Mm-hmm. Will Viking benefit from those pricing coming down with the contract you already have with those CDMO?

Brian Lian
CEO, Viking Therapeutics

Yeah, sure. I mean, we would capture, as efficiencies are achieved, yeah, we would capture those efficiencies as part of the contract, yeah.

Roger Song
Analyst, Jefferies

Okay, got it. All right. Maybe just lastly, on the amylin part, that's another major class for the obesity treatment. So you do have a compound, and then preclinical data looks very intriguing compared to the benchmark. So, what do you want to achieve there? It's a monotherapy combination addressing different population, and then given you're a little bit late, right? I have to admit, right? So, a lot of the peptide amylin already in the market.

Brian Lian
CEO, Viking Therapeutics

Yeah.

Roger Song
Analyst, Jefferies

How are you going to differentiate from this current amylin, just like your VK2735?

Brian Lian
CEO, Viking Therapeutics

Yeah. Amylin's been a little bit of a roller coaster. Enthusiasm's kind of gone up and down and up and down. So, when we first started amylin, we thought it's a nice agent to combine with VK2735. When you combine an amylin with a GLP-1, you typically see a 40%-50% improvement in efficacy. So, we thought if you did that to a dual agonist and saw the same magnitude of benefit, you'd probably see the best in industry weight loss. Now, since our initial thinking, we've seen some companies have success with the single agents, anywhere from 10% to higher teens weight loss. So, we think there's a viable opportunity as a single agent, in patients who are maybe non-responsive to a GLP-1 or intolerant of a GLP-1, in addition to the opportunity in combination with VK2735.

We have a compound, this VK3019, that looks really potent in rodents, really potent in obese primates, at the same dose. It is much more potent than VK2735. Currently in a single ascending dose study in humans. It is wrapping up now. We will go into a multiple ascending dose study in the first quarter and have data probably toward the end of next year from that four-week study. We see the opportunity as both a single agent and in combination.

Roger Song
Analyst, Jefferies

Mm-hmm. Do you see it is combinable, the feasibility of combining with your VK2735 by design? Any kind of formulation or the drug property, it is combinable?

Brian Lian
CEO, Viking Therapeutics

Yeah, we have done a lot of work there with co-formulation, and it seems very encouraging there. At a minimum, we would expect combinable in sort of a dual-chamber device, but ideally, it would be in a single-chamber device.

Roger Song
Analyst, Jefferies

How far away you can kind of nail down the single?

Brian Lian
CEO, Viking Therapeutics

Well, we're doing the combination tox studies today, and we would probably start to move into the initial combo studies after we get the multiple ascending dose study from the VK3019. It's nice to have the You have to sort of map out the profile for the single agents before you really start to explore the combinations. We'll have those data next year.

Roger Song
Analyst, Jefferies

Okay, got it. I believe you have a follow-on for the amylin. The half-life look even longer, and then the potency also pretty good. How far away those come from?

Brian Lian
CEO, Viking Therapeutics

Yeah, the backups, or the follow-ons look really interesting. We think that 3019, we don't have all the data from the SAD study, but we think that's amenable to weekly dosing, which would match up nicely with VK2735. We have a couple of follow-ons that have substantially longer half-lives without a deterioration in efficacy. So very potent, but potentially up to monthly regimens. So, those, we'd like to bring one of those into the clinic, hopefully in the 2027 timeframe, and that would give us a weekly option or potentially a monthly option. Long way away from doing that, but that would be the goal long term, yeah.

Roger Song
Analyst, Jefferies

Excellent. Excellent. Brian, anything else that we haven't touched that you want to highlight to us?

Brian Lian
CEO, Viking Therapeutics

No, I think we've made a lot of progress. We got four phase III trials ongoing. We're still a lean organization, but growing as we prepare for commercialization. First phase III data, we would hope to read out second half of next year. The oral phase III is probably more of a 2028 timeframe. So, really, really busy time at the company.

Roger Song
Analyst, Jefferies

Excellent. Thank you, Brian. Thank you, Greg.

Brian Lian
CEO, Viking Therapeutics

Yep. Thank you.

Roger Song
Analyst, Jefferies

Thank you, everyone.